It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Berberine hydrochloride (BBH) has a variety of pharmacological activities such as antitumor, antimicrobial, anti-inflammation, and reduce irritable bowel syndrome. However, poor stability and low oral bioavailability limited its usage. Herein, an oil-in-water nanoemulsion system of BBH was developed to improve its stability and oral bioavailability. The pseudoternary phase diagrams were constructed for the determination of composition of various nanoemulsions. The nanoemulsions of BBH composed of Labrafil M 1944 CS (oil phase), RH-40 (surfactant), glycerin (co-surfactant), and water (aqueous phase). The O/W nanoemulsion of BBH showed a relative bioavailability of 440.40% compared with unencapsulated BBH and was stable in our 6-month stability study. Further, there was a significant increase in intestinal permeability of BBH as assessed by Caco-2 cell monolayers and a significant reduction in efflux of BBH by the multidrug efflux pump P-glycoprotein. This study confirmed that the nanoemulsion formulation could be used as an alternative oral formulation of BBH to improve its stability, oral bioavailability and permeability.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China;; Key Laboratory of Traditional Chinese Medicine Preparations of Hunan Province, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China;
2 Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China;; Key Laboratory of Traditional Chinese Medicine Preparations of Hunan Province, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China;; Hunan Cancer Hospital, Changsha, Hunan, China;
3 Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China;; Institute of Clinical Pharmacy, Central South University, Changsha, Hunan, China
4 Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China;; Key Laboratory of Traditional Chinese Medicine Preparations of Hunan Province, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China;; Institute of Clinical Pharmacy, Central South University, Changsha, Hunan, China